ERBB2 and breast cancer: The HER2-low category is defined by a HER2 score of 1+ or 2+ without detectable gene amplification and accounts for 40–60% of BC cases (with some studies reporting frequencies up to 70%), representing a large group of patients with potential benefit from new forms of HER2-targeted therapy in the metastatic or locally advanced setting [7, 10–13].